Jay. I have been following your posts . Can you comment on my understanding below . The Australian subsidiary pays license fee to humanigen for lenz. It’s owned by humanigen which was excluded from the sale to Taran . Taran owns the license now for lenz. The clinical trial is being conducted by the subsidiary in Australia. The Australian subsidiary may receive the approval for lenz if it gets through the trial . That’s the value that’s been left behind . Taran would continue to receive the license fees for any potential sales by the Australian subsidiary post approval . Humanigen’s value now is in the subsidiary.
News 
Market Data 
Discover 
